Literature DB >> 657590

Production of the complement cleavage product, C3a, by activated macrophages and its tumorolytic effects.

J Ferluga, H U Schorlemmer, L C Baptista, A C Allison.   

Abstract

Mouse peritoneal macrophages were activated in serum-free culture with lipopolysaccharide, dextran sulphate or C3b. They were found to liberate into the culture medium a cytolytic factor and a factor which was pharmacologically indistinguishable from C3a. The cytolytic activity was neutralized by antiserum against C3a. These results suggest that macrophages can be activated by C3b (or agents that generate C3b) to cleave C3, which they themselves produce. In this way the activated macrophages form C3a, which appears to be a major factor in macrophage-mediated cytolysis. These findings have implications in tumour immunity and in the pathogenesis of inflammatory reactions.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 657590      PMCID: PMC1541251     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  17 in total

1.  Effects of activated complement components on enzyme secretion by macrophages.

Authors:  H U Schorlemmer; A C Allison
Journal:  Immunology       Date:  1976-11       Impact factor: 7.397

2.  Interaction of C3b, B, and D in the alternative pathway of complement activation.

Authors:  A Nicholson; V Brade; H U Schorlemmer; R Burger; D Bitter-Suermann; U Hadding
Journal:  J Immunol       Date:  1975-10       Impact factor: 5.422

3.  Induction of macrophage-mediated tumor-cell cytotoxicity by pyran copolymer.

Authors:  A M Kaplan; P S Morahan; W Regelson
Journal:  J Natl Cancer Inst       Date:  1974-06       Impact factor: 13.506

4.  In vitro inhibition of tumour cell growth and DNA synthesis by peritoneal and lung macrophages from mice injected with Corynebacterium parvum.

Authors:  M Olivotto; R Bomford
Journal:  Int J Cancer       Date:  1974-04-15       Impact factor: 7.396

5.  In vitro synthesis of factor B of the alternative pathway of complement activation by mouse peritoneal macrophages.

Authors:  C Bentley; D Bitter-Suermann; U Hadding; V Brade
Journal:  Eur J Immunol       Date:  1976-06       Impact factor: 5.532

6.  Corynebacterium parvum as a therapeutic antitumor agent in mice. I. Systemic effects from intravenous injection.

Authors:  M T Scott
Journal:  J Natl Cancer Inst       Date:  1974-09       Impact factor: 13.506

7.  Cytotoxicity mediated by soluble macrophage product(s).

Authors:  K K Sethi; H Brandis
Journal:  J Natl Cancer Inst       Date:  1975-08       Impact factor: 13.506

8.  In vitro synthesis of some complement components (C1q, C3 and C4) by lymphoid tissues and circulating leucocytes in man.

Authors:  R F Lai A Fat; R van Furth
Journal:  Immunology       Date:  1975-02       Impact factor: 7.397

9.  Gross and ultrastructural observations on lesions produced by intradermal injection of human C3a in man.

Authors:  I H Lepow; K Willms-Kretschmer; R A Patrick; F S Rosen
Journal:  Am J Pathol       Date:  1970-10       Impact factor: 4.307

10.  The derivation of two distinct anaphylatoxin activities from the third and fifth components of human complement.

Authors:  C G Cochrane; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1968-02-01       Impact factor: 14.307

View more
  33 in total

1.  Interferon gamma encapsulated into liposomes enhances the activity of monocytes and natural killer cells and has antiproliferative effects on tumor cells in vitro.

Authors:  I Rutenfranz; A Bauer; H Kirchner
Journal:  Blut       Date:  1990-07

Review 2.  The role of macrophage activation in chronic inflammation.

Authors:  A C Allison; J Ferluga; H Prydz; H U Schorlemmer
Journal:  Agents Actions       Date:  1978-01

3.  Release of cartilage proteoglycan degrading enzyme activity by thioglycollate stimulated mouse peritoneal macrophages in culture.

Authors:  N Ackerman; S Jubb; B Trimble; B Yoxall
Journal:  Agents Actions       Date:  1979-12

Review 4.  Mechanisms of macrophage activation.

Authors:  H M Ogmundsdóttir; D M Weir
Journal:  Clin Exp Immunol       Date:  1980-05       Impact factor: 4.330

5.  Destruction of tumor cells by monokines released from activated human blood monocytes: evidence for parallel and additive effects of IL-1 and TNF.

Authors:  Y Ichinose; J Y Tsao; I J Fidler
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

6.  Differential effects of BCNU on T cell, macrophage, natural killer and lymphokine-activated killer cell activities in mice bearing a syngeneic tumor.

Authors:  M Nagarkatti; P S Nagarkatti; A M Kaplan
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

7.  Phagocytosis stimulates the release of a slow reacting substance in cultured macrophages.

Authors:  U Bretz; B Dewald; T Payne; J Schnyder
Journal:  Br J Pharmacol       Date:  1980       Impact factor: 8.739

8.  Ultrastructural studies of the interaction between liposome-activated human blood monocytes and allogeneic tumor cells in vitro.

Authors:  C D Bucana; L C Hoyer; A J Schroit; E Kleinerman; I J Fidler
Journal:  Am J Pathol       Date:  1983-07       Impact factor: 4.307

9.  Production of an anti-tumour cytotoxin by human monocytes.

Authors:  N Matthews
Journal:  Immunology       Date:  1981-09       Impact factor: 7.397

10.  Immunological studies on drug-induced allergic hepatitis--hepatocellular injury by macrophage-mediated cytotoxicity.

Authors:  Y Mizoguchi; T Shiba; F Ohnishi; T Monna; S Yamamoto; S Otani; S Morisawa
Journal:  Gastroenterol Jpn       Date:  1980
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.